TheraRadar
Data updated: May 26, 2026

SEYSARA (sarecycline hydrochloride)

Dermatology Approved 2018-10-01

SEYSARA is indicated for the treatment of Acne Vulgaris.

Source: FDA Label • ALMIRALL

How SEYSARA Works

Sarecycline is an aminomethylcycline within the tetracycline class of drugs. The specific mechanism of action of Seysara in treating the inflammatory lesions of non-nodular acne vulgaris is not known.

1
Indication
--
Phase 3 Trials
7
Years on Market

Details

Status
Prescription
First Approved
2018-10-01
Patent Cliff
2033

Pro Metrics

Patent cliff and revenue data

Unlock with Pro
Routes
ORAL
Dosage Forms
TABLET

Companies

Active Ingredient: SARECYCLINE HYDROCHLORIDE

SEYSARA Approval History

2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
15 FDA actions from 2018 to 2023
Mar 2023 SUPPL
Label · Labeling
Jun 2020 SUPPL
Label · Labeling
Apr 2019 SUPPL
Label · Labeling

What SEYSARA Treats

1 indications

SEYSARA is approved for 1 conditions since its original approval in 2018. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Acne Vulgaris
Source: FDA Label

SEYSARA Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 8 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to SEYSARA

3 of 20

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

ACANYA
BENZOYL PEROXIDE
1 shared
BAUSCH
Shared indications:
ACZONE
DAPSONE
1 shared
ALMIRALL
Shared indications:
ADAPALENE AND BENZOYL PEROXIDE
ADAPALENE
1 shared
PADAGIS ISRAEL
Shared indications:
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

SEYSARA FDA Label Details

Indications & Usage

FDA Label (PDF)

SEYSARA is indicated for the treatment of Acne Vulgaris.

View full patent landscape →
4 OB patents · 3 families · 114 international docs across 21 countries

SEYSARA Patents & Exclusivity

Latest Patent: Feb 2033

Patents (4 active)

US9255068 Expires Feb 9, 2033
US8318706 Expires Jan 3, 2032
US8513223 Expires Dec 7, 2029
US9481639 Expires Aug 10, 2028
Source: FDA Orange Book

Pro Intelligence Preview

Deep insights for SEYSARA

Revenue Insights

  • Quarterly revenue tracking
  • Historical trend analysis

Patent Timeline

  • Cliff: 2033
  • 45 active patents

Trial Analysis

  • Clinical trial tracking
  • Development stage analysis

Competitive Landscape

  • 20 similar drugs
  • Same target/indication analysis
Unlock Full Intelligence

Full approval history • All patents • Revenue trends • Competitor analysis

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.